Generated by Meeveem AI
"Developing in vivo cell reprogramming therapies for degenerative diseases"
Mogrify develops treatments for degenerative diseases using proprietary cell reprogramming platforms. The company's MOGRIFY and epiMOGRIFY technologies identify transcription factors needed to convert any cell type into another, enabling the body to regenerate lost or damaged cells directly in situ. This approach targets otology, ophthalmology and diabetes where cells are lost to disease or injury. The platforms use systematic analysis of transcriptomic and epigenetic data to predict optimal reprogramming factors. This restores organ function by recovering functional cell types where needed, without transplantation. Patients with hearing loss, vision disorders and metabolic diseases benefit from these in vivo therapies.
25
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where degenerative diseases no longer cause irreversible cell loss, with organs able to regenerate functional tissue naturally through precise cellular reprogramming at the site of injury or illness.
Mogrify's mission is to transform the lives of patients through the development of a novel class of in vivo reprogramming therapies.